Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review (Q37896165)

25 August 2017

1 reference

title

Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review (English)

1 reference

25 August 2017

anti-retroviral agent

0 references

1 reference

1

Katharina Kranzer

1 reference

25 August 2017

2

Nathan Ford

1 reference

25 August 2017

1 July 2011

1 reference

Tropical Medicine and International Health

25 August 2017

17

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

16

1 reference

25 August 2017

10

1 reference

25 August 2017

1297-1313

1 reference

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Revisiting Long-Term Adherence to Highly Active Antiretroviral Therapy in Senegal Using Latent Class Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Sustained HIV viral suppression following treatment interruption: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Improvements in antiretroviral therapy outcomes over calendar time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

A systematic review of adherence with medications for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Medication compliance and persistence: terminology and definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Correlates of antiretroviral treatment breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Nonstructured treatment interruptions among injection drug users in Baltimore, MD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

The impact of antiretroviral therapy in a cohort of HIV infected patients going in and out of the San Francisco county jail

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Immunological changes during treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Self-Reported Adherence to Antiretroviral Therapy for HIV-1 Infection and Virologic Treatment Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

Immunologic and Virologic Consequences of Temporary Antiretroviral Treatment Interruption in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02828.X

10.1111/J.1365-3156.2011.02828.X

21 January 2018

Identifiers

DOI

1 reference

release_x7m2gsrx7zgavja4jpsbc2lyae

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x7m2gsrx7zgavja4jpsbc2lyae

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21718394

1 reference

PubMed ID

21718394